Table 5.16Cost-effectiveness results - McMurray 2006 economic analysis*

CHARM TrialIncremental cost (£)Incremental effect - Life-year gained (LYG) (95%CI)UK results – Cost/LYG (95%CI)¥
Alternative£51±£771/year**0.078 (0.003–0.15)£1706 (dominant¥¥; £709,631)
Added£10±£210/year**0.061 (−0.002–0.12)Dominant¥¥

When developing the analysis, unit costs in pound sterling were converted into Euro using 1 Euro = 0.67 GBP. We used the same converted rate to present results in pound sterling.


Median follow-up of 41 months for CHARM-Added and of 34 months for CHARM-Alternative


Using the utility score proposed by Mant 200937 of 0.65 for patients with heart failure, we estimated the threshold in cost per LYG equivalent to the £20,000 per QALY gained proposed by NICE to be £13,000 per LYG.


‘Dominant’ means that adding candesartan to optimal medical management is more effective and less costly than adding placebo.

From: 5, Treating heart failure

Cover of Chronic Heart Failure
Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update [Internet].
NICE Clinical Guidelines, No. 108.
National Clinical Guideline Centre (UK).
Copyright © 2010, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.